Pelican Bay Capital Management (PBCM), an investment management company, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. PBCM Concentrated Value Strategy returned 8.5% in the quarter, compared to a 3.8% return for the Russell 1000 Value Index. The robust performance of AI-related stocks and commodities exposure drove the Strategy’s performance in the quarter. For the full year, the Strategy returned 20.6% compared to 15.9% for the Index. The firm seeks to inve ...

Zoetis Inc. (ZTS), with a market cap of $56.3 billion, is a leading animal health company that discovers, develops, manufactures, and commercializes a broad portfolio of medicines, vaccines, diagnostic products, and precision health solutions for livestock and companion animals worldwide. The company is headquartered in Parsippany, New Jersey. Shares of the company have underperformed the broader market over the past 52 weeks. ZTS has decreased 27.5% over this time frame, while the broader S&P 500 Index ...

The market expects Zoetis (ZTS) to deliver flat earnings compared to the year-ago quarter on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be rel ...

In the latest close session, Zoetis (ZTS) was down 2.02% at $122.41. The stock fell short of the S&P 500, which registered a loss of 0.84% for the day. Meanwhile, the Dow lost 0.34%, and the Nasdaq, a tech-heavy index, lost 1.43%. Prior to today's trading, shares of the animal health company had lost 3.42% lagged the Medical sector's gain of 0.16% and the S&P 500's gain of 1.8%.Analysts and investors alike will be keeping a close eye on the performance of Zoetis in its upcoming earnings disclosure. The comp ...

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Zoetis (ZTS) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a pr ...

The fourth-quarter 2025 reporting cycle for the Medical sector is about to pick up pace this week, as most firms are slated to share their earnings results over the next two weeks. The sector mainly comprises pharma/biotech and medical device companies. The earnings season for the drug and biotech sector kicked off in late January when bellwether Johnson & Johnson reported strong fourth-quarter results, beating estimates for earnings and sales. While most of the pharma bigwigs are slated to report their ear ...

Diamond Hill Capital, an investment management company, released its “Large Cap Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets continued their upward momentum in Q4, with the Russell 1000 Value Index increasing 3.8%. The information technology (+11%) and communication services (+9%) sectors are leading the rally, driven by AI optimism. The growth areas of the market accounted for the majority of the Index’s return in Q4. The firm maintains a cautious s ...

Market Performance - The broad U.S. market started the year positively, with the SPDR® S&P 500® ETF (SPY) posting a gain despite some elevated volatility in the final week of January [1]

Group 1 - Zoetis Inc. (NYSE:ZTS) is recognized as one of the most profitable healthcare stocks to consider for investment, with a current price target of $130 set by Stifel Nicolaus, indicating a potential upside of 4.91% [1] - Piper Sandler downgraded Zoetis from Overweight to Neutral, reducing the price target from $190 to $135, citing concerns over the company's innovation timeline and projecting a potential "innovation air pocket" lasting one to two years [2] - Morgan Stanley also adjusted its price target for Zoetis, lowering it from $175 to $160 while maintaining an Overweight rating, suggesting a favorable environment for healthcare companies in 2026 despite current challenges in managed care stocks [3] Group 2 - Zoetis Inc. is a New Jersey-based company established in 1950, specializing in a range of health products including animal health medicines, vaccines, biodevices, and genetic tests, with a goal to become the most valuable animal health company [4]

智通财经APP获悉，在黄金、白银等硬商品行情持续吸引市场目光之际，软商品板块正悄悄积累动能， 逐步走进"舞台"中央。谷物、畜牧、乳制品等农业相关品种近期整体走强，也带动覆盖农业全产业链获 得关注。 农产品加工与贸易板块中，Archer Daniels Midland(ADM.US)年内已上涨约17%，股息率接近3%。股价 逼近52周高点，并完成关键65美元关口的向上突破，周线图呈现"倒头肩底"形态。同行邦吉(BG.US)同 期上涨约25%，形成良好的同业验证。若后续有效站稳200周均线，上行空间或进一步打开，年内目标 被看至90美元。 防御型食品板块方面，美国达尔令国际(DAR.US)过去三个月累计上涨约23%，五周连涨，周线50周均 线多年后首次拐头向上。股价近期突破40美元关键阻力位，若守住37美元上方，中期或指向55美元。 在个股层面，部分农业相关股票已率先走强并进入技术性整固阶段。此前两周累计上涨近20%的 Nutrien(NTR.US)，便被视为强势标的之一。与此同时，市场开始将目光投向仍具上行潜力的品种。 化肥与基础材料板块方面，CF工业控股(CF.US)年初至今涨幅已超过18%，并录得四周连涨， ...